BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gradually progress to cirrhosis. It is generally associated with obesity, diabetes and hyperlipidemia. Currently, there is no established therapy for NASH. The aim of the present study was to evaluate the effectiveness of atorvastatin and ursodeoxycholic acid (UDCA) in the treatment of NASH
<p>Results of combined therapy of gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD)...
NASH associates steatosis with parenchymal inflammation and signs of hepatocellular injuy and even a...
Many interventions have been investigated for the treatment of nonalcoholic steatohepatitis (NASH). ...
BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gra...
Non-alcoholic steatohepatitis (NASH) has a prevalence of 1% in Western countries. Its causes as well...
Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activ...
Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range i...
BACKGROUND ; AIMS: Nonalcoholic steatohepatitis (NASH) is a frequent liver disease that can progress...
Background Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease that is increasingly bei...
International audienceBACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is a prevalent liver di...
Nonalcoholic steatohepatitis (NASH) has emerged as one of the important causes of cirrhosis and hepa...
Objective: The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NA...
Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and hepatocellular bal...
IntroductionNon-alcoholic fatty liver disease (NAFLD) has become the most common etiology for abnorm...
Non-alcoholic fatty liver disease (NAFLD) is on a leading position among chronic liver diseases. In ...
<p>Results of combined therapy of gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD)...
NASH associates steatosis with parenchymal inflammation and signs of hepatocellular injuy and even a...
Many interventions have been investigated for the treatment of nonalcoholic steatohepatitis (NASH). ...
BACKGROUND/AIMS: Nonalcoholic steatohepatitis (NASH) is a serious disorder with the potential to gra...
Non-alcoholic steatohepatitis (NASH) has a prevalence of 1% in Western countries. Its causes as well...
Non-alcohol-induced steatohepatitis (NASH) is characterized by elevated serum aminotransferase activ...
Non-alcoholic fatty liver disease (NAFLD) is the primary cause of chronic liver disease. The range i...
BACKGROUND ; AIMS: Nonalcoholic steatohepatitis (NASH) is a frequent liver disease that can progress...
Background Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease that is increasingly bei...
International audienceBACKGROUND & AIMS: Nonalcoholic steatohepatitis (NASH) is a prevalent liver di...
Nonalcoholic steatohepatitis (NASH) has emerged as one of the important causes of cirrhosis and hepa...
Objective: The prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis (NA...
Non-alcoholic steatohepatitis (NASH) is characterized by lobular inflammation and hepatocellular bal...
IntroductionNon-alcoholic fatty liver disease (NAFLD) has become the most common etiology for abnorm...
Non-alcoholic fatty liver disease (NAFLD) is on a leading position among chronic liver diseases. In ...
<p>Results of combined therapy of gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD)...
NASH associates steatosis with parenchymal inflammation and signs of hepatocellular injuy and even a...
Many interventions have been investigated for the treatment of nonalcoholic steatohepatitis (NASH). ...